Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 14–Jun 21, 2026)
One FDA decision date falls in this week: ACHV’s NDA for nicotine dependence, with a June 20 target date. On the Run-up Radar, UNCY’s NDA decision is 15 days out, and IBRX and AXSM have trial milestones in 17 days. TNGX was last week’s biggest biotech gainer, up 53%.
💊 FDA Decisions (PDUFA Dates)
| Date | Ticker | Drug | Indication | Type |
|---|---|---|---|---|
| 2026-06-20 | ACHV | — | nicotine dependence | NDA |
📡 Run-up Radar Highlights
Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):
- UNCY: NDA in 15 days, score 72/100
- IBRX: Phase 2, Recruiting in 17 days, score 55/100
- AXSM: Phase 2, Recruiting in 17 days, score 53/100
📈 Last Week’s Biggest Gainers
- TNGX +52.97% (volume 6.5x average)
- NUVL +39.28% (volume 77.0x average)
Track your tickers on the BioRadar dashboard →
This digest is for informational purposes only and is not investment advice. Always do your own research.